Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Hepcludex Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentEmpire BluecrossPolicy CC-0303

    Hepcludex (bulevirtide-gmod) Coverage for Chronic Hepatitis Delta Virus Infection

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0303 alerts

    Get alerted when Policy CC-0303 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity review for Hepcludex (bulevirtide-gmod) used to treat chronic hepatitis delta virus infection in adults. It applies to providers requesting initial or continuation coverage under the member's applicable benefit.

    Policy Summary
    PayerEmpire Bluecross
    PolicyHepcludex (bulevirtide-gmod) Coverage for Chronic Hepatitis Delta Virus Infection
    Policy CodePolicy CC-0303
    Change TypeNew policy
    Effective DateJul 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of chronic HDV infection, elevated ALT greater than 1 times the ULN, and cirrhosis status for initial requests.
    SourceLink
    POLICY UPDATE CHANGES

    A new clinical criteria document was added for Hepcludex (bulevirtide-gmod).

    HCPCS codes C9399 and J3590 and ICD-10-CM code B18.0 were added for Hepcludex-related coding.

    18+Minimum age for initial approval
    >1× ULNRequired elevated ALT level
    1 vial/dayHepcludex quantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 year
    Approval duration

    Coverage Criteria

    Initial Therapy

    Initial requests for Hepcludex (bulevirtide-gmod) may be approved when ALL of the following criteria are met:

    ALL of the following

    • Individual is 18 years of age or older.
    • Individual has a diagnosis of chronic hepatitis delta (D) virus (HDV) infection.
    • Individual does not have cirrhosis, or has compensated cirrhosis.
    • Documentation is provided that chronic HDV infection is verified by the presence of positive serum anti-hepatitis delta virus (HDV) antibody or HDV RNA.
    • Individual has an elevated alanine transaminase (ALT) level greater than 1 times the upper limit of normal (ULN).> 1 times ULN

    Continuation Therapy

    Continuation requests for Hepcludex (bulevirtide-gmod) may be approved when ALL of the following criteria are met:

    ALL of the following

    • Documentation is provided that the individual has a decrease in HDV RNA.
    • Individual has normalization of alanine transaminase (ALT) levels.

    Coding Information

    HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Hepcludex (bulevirtide-gmod)]
    J3590Unclassified biologics [when specified as Hepcludex (bulevirtide-gmod)]
    ICD-10 DiagnosisICD-10
    B18.0Chronic viral hepatitis B with delta-agent
    Alanine Transaminase
    Laboratory testAlanine transaminase (ALT)
    Required levelGreater than 1 times the upper limit of normal (ULN)
    Applies toInitial Hepcludex approval requests

    Provider Actions and Review Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required when Hepcludex (bulevirtide-gmod) is subject to clinical review. The request must satisfy the applicable initial or continuation clinical criteria before coverage may be approved.

    • Initial requests are reviewed against all five initial-therapy criteria.
    • Continuation requests are reviewed against both continuation-response criteria.
    Documentation Required

    Initial Clinical Documentation Required

    For an initial Hepcludex request, submit documentation supporting all applicable criteria.

    • Individual is 18 years of age or older.
    • Diagnosis of chronic hepatitis delta (D) virus (HDV) infection.

    Clinical Background

    Hepcludex (bulevirtide-gmod) is a sodium taurocholate co-transporting polypeptide (NTCP)-directed HDV attachment inhibitor. It binds to and inactivates NTCP, a bile salt liver transporter that serves as an essential entry receptor, thereby blocking entry of hepatitis B virus (HBV) and hepatitis delta virus (HDV) into hepatocytes.

    Chronic HDV infection occurs only in individuals who are also infected with HBV and represents the most severe form of chronic viral hepatitis, with more rapid progression toward liver-related death and hepatocellular carcinoma. Active infection may be assessed by HDV RNA testing after detection of anti-HDV antibodies. The optimal duration of Hepcludex treatment is unknown; labeling indicates that treatment should continue while it remains associated with a treatment response.

    Definitions

    Chronic Hepatitis Delta Virus Infection
    Also calledHepatitis D or delta hepatitis
    CauseLiver infection caused by hepatitis D virus (HDV)
    Relationship to HBVOccurs only in people who are also infected with hepatitis B virus (HBV)
    NTCP
    Full nameSodium taurocholate co-transporting polypeptide
    FunctionBile salt liver transporter
    Role in infectionEssential HBV and HDV entry receptor; Hepcludex binds to and inactivates it

    Initial Therapy

    Continuation Therapy

    Continuation Therapy Authorization Decision Tree

    Continuation requests may be approved only when ALL response requirements are documented:

    Continuation authorization

    • Virologic response

      • Documentation is provided that the individual has a decrease in HDV RNA.Decrease in HDV RNA

        Required for continuation authorization.

    • Biochemical response

      • The individual has normalization of alanine transaminase (ALT) levels.ALT normalization

        Required for continuation authorization.

    Quantity Limits

    Quantity Limits
    DrugHepcludex (bulevirtide-gmod)
    Strength and form8.5 mg vial
    Quantity limit1 vial per day
    Policy Summary
    PayerEmpire Bluecross
    PolicyHepcludex (bulevirtide-gmod) Coverage for Chronic Hepatitis Delta Virus Infection
    Policy CodePolicy CC-0303
    Change TypeNew policy
    Effective DateJul 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of chronic HDV infection, elevated ALT greater than 1 times the ULN, and cirrhosis status for initial requests.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Actions and Review RequirementsClinical BackgroundDefinitionsInitial TherapyContinuation TherapyQuantity Limits
  1. No cirrhosis, or compensated cirrhosis.
  2. Chronic HDV infection verified by positive serum anti-HDV antibody or HDV RNA.
  3. Elevated alanine transaminase (ALT) level greater than 1 times the upper limit of normal (ULN).
  4. Documentation Required

    Continuation Response Documentation

    For a continuation request, provide response documentation demonstrating that both treatment-response criteria are met.

    • Decrease in HDV RNA.
    • Normalization of alanine transaminase (ALT) levels.
    Denial Risk

    Initial Criteria Not Met

    An initial request may be denied when the required initial clinical criteria are not met or the supporting documentation is not provided.

    • Any one of the five initial criteria is not satisfied.
    • Required documentation is missing or does not verify the diagnosis, disease status, cirrhosis status, or elevated ALT level.
    Denial Risk

    Continuation Response Not Documented

    A continuation request may be denied when the required treatment response is not documented.

    • Documentation does not show a decrease in HDV RNA.
    • Documentation does not show normalization of ALT levels.
    • Documentation is insufficient to establish both continuation criteria.
    HDV RNA
    Test methodDetected by polymerase chain reaction (PCR)
    What it indicatesEvidence of active HDV infection when present
    Clinical significanceProvides evidence of active HDV replication